| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Immediate Pharmaceutical Services is a Avon Lake, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Flo Healthcare is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2003, Valeo Pharma is a Canadian Pharma Company with a long history of successfully driving #healthcareinnovationforcanadians by commercializing pharmaceutical products in Canada and is therapeutically focused on respiratory diseases, neurodegenerative diseases, specialty products, and oncology.
Nostrum Laboratories is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.